Solfoton Side Effects
Generic Name: phenobarbital
Note: This page contains side effects data for the generic drug phenobarbital. It is possible that some of the dosage forms included below may not apply to the brand name Solfoton.
For the Consumer
Applies to phenobarbital: oral elixir, oral tablets, parenteral injection
Side effects include:
Residual sedation, drowsiness, lethargy, vertigo, nausea, vomiting, headache.
For Healthcare Professionals
Applies to phenobarbital: compounding powder, injectable solution, oral capsule, oral elixir, oral tablet
The most commonly reported side effect was somnolence.[Ref]
Common (1% to 10%): Somnolence
Postmarketing reports: Sedation, residual sedation/"hangover" effect, drowsiness, lethargy, vertigo, localized/diffuse neuralgic pain, headache, hyperactivity, hypotension, hyperkinesia, ataxia, central nervous system (CNS) depression, dizziness, impairment of fine motor skills, Grand mal convulsion, prolonged coma, depressed/absent reflexes, nystagmus[Ref]
Drowsiness/sedation tended to decrease with continued use.
Localized or diffuse neuralgic pain occurred, especially in psychoneurotic patients with insomnia. This pain was most frequently located in the neck, shoulders, and upper limbs and appeared in paroxysms that were most intense early in the morning. In some patients, the pain continued for days after discontinuation of this drug.
Hyperactivity occurred in pediatric and geriatric patients.[Ref]
Postmarketing reports: Accentuated emotional disturbances/phobias, aggression, excitement/hyperexcitability, restlessness, delirium, irritability, agitation, confusion, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia/sleep disturbance, anxiety, abnormality in thinking, paradoxical reaction (unusual excitement), mental depression/depression, cognitive impairment, behavioral disturbances in children, abnormal behavior, mood altered, subtle mood changes, menstrually related mood disorder, suicidal ideation, memory/concentration/judgment impairment, withdrawal syndrome, tolerance, dependence, psychic/physical dependence, mental confusion/confusion, disorientation[Ref]
Some patients have experienced paradoxical excitement, restlessness, or delirium in the presence of pain.
Paradoxical reactions, hallucinations, restlessness, hyperexcitability, and confusion have occurred in geriatric and pediatric patients. Pediatric patients were more likely to experience aggression or irritability.[Ref]
Postmarketing reports: Antiepileptic hypersensitivity syndrome (e.g., fever, rash, lymphadenopathy, lymphocytosis, eosinophilia, hematological abnormalities, hepatic and other organ involvement [renal, pulmonary])[Ref]
Antiepileptic hypersensitivity syndrome typically occurred 1 to 8 weeks after first exposure or within 1 day of rechallenge. This syndrome may have cross reactivity with other antiepileptic agents.[Ref]
Skin eruptions may be associated with fever, delirium, and marked changes in the liver and other organs.[Ref]
Postmarketing reports: Erythematous dermatitis, exfoliative dermatitis (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), skin eruptions, maculopapular/morbilliform/scarlatiniform rashes, dermatitis, erythema multiforme, drug eruption, evidence of connective tissue changes, skin blisters/bullae, photosensitivity, erythroderma, urticaria[Ref]
Postmarketing reports: Localized/diffuse myalgic or arthritic pain, osteomalacia, rickets, decreased bone mineral density, increased risk of fracture, Dupuytren's contracture, bone metabolism disorder, frozen shoulder, Ledderhose's syndrome, general joint pain, osteopenia, osteoporosis, fractures[Ref]
Localized or diffuse myalgic or arthritic pain occurred, especially in psychoneurotic patients with insomnia. This pain was most frequently located in the neck, shoulders, and upper limbs and appeared in paroxysms that were most intense early in the morning. In some patients, pain continued for days after discontinuation of therapy.
Decreased bone mineral density, Dupuytren's contracture, osteopenia, osteoporosis, and fractures occurred in patients receiving long-term therapy; however, the exact mechanism of action in bones was not identified.[Ref]
Postmarketing reports: Inebriation (drunk-like effect), fever, neonatal sedation, neonatal drug dependence/withdrawal, neonatal symptoms resembling vitamin K deficiency, neonatal bleeding due to vitamin K deficiency, congenital anomaly, cleft lip and palate, lowered body temperature[Ref]
Postmarketing reports: Megaloblastic anemia, macrocytic anemia, aplastic anemia, agranulocytosis, thrombocytopenia, hypoprothrombinemia, methemoglobinemia, purpura, lymphocytosis[Ref]
Megaloblastic anemia occurred after chronic use of this drug, and may be due to folate deficiency.
Methemoglobinemia has occurred in infants nursed by mothers receiving this drug.[Ref]
Postmarketing reports: Circulatory collapse, peripheral vascular collapse, weak heartbeat, circulatory failure, bradycardia, hypotension, profound shock, vasodilation[Ref]
Postmarketing reports: Respiratory depression, severe/significant respiratory depression, apnea, hypoventilation, bronchospasm, laryngospasm[Ref]
Bronchospasm and laryngospasm were reported, especially in patients given the IV formulation.[Ref]
Postmarketing reports: Abnormal hepatic function, hepatitis, liver damage, cholestasis, toxic hepatitis, jaundice[Ref]
Postmarketing reports: Hypocalcemia, folate deficiency, abnormal vitamin D metabolism, increased vitamin D requirements (possibly resulting from abnormal vitamin D metabolism), vitamin K deficiency, hypophosphatemia[Ref]
Postmarketing reports: Nausea, vomiting, constipation, diarrhea[Ref]
Hypersensitivity reactions generally consisted of acquired hypersensitivity. Patients with a higher risk of developing reactions were more likely to have asthma, urticaria, and angioedema.[Ref]
Postmarketing reports: Localized swelling (e.g. eyelids, cheeks, lips), hypersensitivity reactions (e.g., angioedema, skin rashes, exfoliative dermatitis), angioedema[Ref]
Postmarketing reports: Injection site reactions, local necrosis after extravasation (IV/subcutaneous injection)[Ref]
Postmarketing reports: Renal failure[Ref]
Postmarketing reports: Fibromas[Ref]
Postmarketing reports: Reduced serum concentrations of thyroid hormones[Ref]
Postmarketing reports: Peyronie's disease[Ref]
1. "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
It is possible that some side effects of Solfoton may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
More about Solfoton (phenobarbital)
- Other brands: Luminal
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.